Genmab reported 1.25B in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agios Pharmaceuticals AGIO:US $ -94.94M 3.5M
Amarin AMRN:US $ -62.83M 34.52M
Amgen AMGN:US $ 2176M 324M
Artemis Alpha ATS:LN -10207000 58.81M
AstraZeneca AZN:LN 539M 339M
Bayer BAYN:GR 169M 4.04B
Biomarin Pharmaceutical BMRN:US $ 39.15M 98.18M
Bluebird Bio BLUE:US $ -107.4M 12.95M
Exelixis EXEL:US $ 83.71M 0.46M
Fresenius Medical Care FME:GR € 341M 6.67M
Galapagos GLPG:NA -76332000 55.19M
Genmab GEN:DC 1.25B 733M
GlaxoSmithKline GSK:LN 1.08B 1.72B
GN Store Nord GN:DC -106000000 636M
Hikma Pharmaceutical HIK:LN 249M 6M
Immunogen IMGN:US $ -61.05M 38.2M
Insmed INSM:US $ -88316000 1.52M
Lonza Group LONN:SW 645M 111M
Merck MRK:GR € 1177M 4M
Novartis NOVN:VX 2.23B 624M
Regeneron Pharmaceuticals REGN:US $ 1109.9M 148.6M
Seattle Genetics SGEN:US $ -133.11M 0.06M